Clinical Trial Update: A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the cardiac effects of siltuximab in patients with Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monoclonal Gammopathy of Undetermined Significance
• Multiple Myeloma

Drugs mentioned

• Sylvant (siltuximab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma | Phase 1 | Status: COMPLETED